SCHEMBL8286923

SCHEMBL8286923

O=C(CCCCCC(=O)N(CC(=O)Nc1cccc(Oc2ccccc2)c1)CC(=O)Nc1cccc(Oc2ccccc2)c1)NO

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 16/20 0.63
▸ HDAC2 Q92769 10/20 0.63
▸ HDAC6 Q9UBN7 9/20 0.63
▸ HDAC11 Q96DB2 8/20 0.63
▸ HDAC8 Q9BY41 8/20 0.63
▸ HDAC4 P56524 7/20 0.63
▸ HDAC7 Q8WUI4 7/20 0.63
▸ HDAC9 Q9UKV0 7/20 0.63
▸ HDAC5 Q9UQL6 7/20 0.63
▸ HDAC3 O15379 7/20 0.63
▸ HDAC10 Q969S8 7/20 0.63
▸ MITF O75030 1/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ NCOR2 Q9Y618 2/20 0.53
▸ EGFR P00533 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ BRD4 O60885 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8285480 0.88 HDAC1 (0.57) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL8284504 0.88 HDAC1 (0.57) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL8286315 0.86 HDAC1 (0.72) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL8284505 0.83 L3MBTL1 (0.58) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL8285419 0.78 HDAC1 (0.61) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL8285326 0.78 HDAC1 (0.61) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL8285469 0.77 HDAC1 (0.59) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL10207293 0.77 HDAC1 (0.63) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL7451167 0.76 HDAC1 (0.70) HDAC1HDAC2HDAC6HDAC11HDAC8
SCHEMBL8286918 0.76 HDAC1 (0.74) HDAC1HDAC2HDAC6HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 — — US disclosed
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 — — US disclosed
WO-2005053610-A2 DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES ATON PHARMA, INC. (US) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives AADAC, BRDT, HDAC5 HDAC1 5/4885HDAC2 7/4885HDAC6 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback